China approves AstraZeneca, Sanofi shot to prevent RSV infection
时间:2024-06-26 05:04:28 阅读(143)
China approved a shot co-developed by AstraZeneca Plc and Sanofi to ward off respiratory syncytial virus in a broad swath of infants, a first in the nation to thwart the highly contagious and potentially fatal infection.
The National Medical Products Administration cleared the long-acting monoclonal antibody Beyfortus to prevent RSV infections in newborns, Astra said in a statement on Tuesday. While RSV has been circulating in China for months, the shot isn’t expected to be available until the upcoming 2024-2025 season, the company said.
RSV causes inflammation of the airways that can lead to difficulty breathing and death in rare cases. Beyfortus is among the first medicines available for widespread use to protect infants from the illness, which affects most children by the age of two.
China has confronted an outsized outbreak of respiratory diseases since the second half of 2023, with children particularly hard hit by a barrage of common pathogens including RSV, flu and mycoplasma pneumoniae. The surge in disease has stretched some pediatric medical centers across the country beyond capacity.
猜你喜欢
- Cyclone Biparjoy leaves trail of devastation in Gujarat – SEE PICS
- Tata Motors’ engineering unit files papers for IPO
- ITC only Sensex stock in green as share price jumps 4% after Q4 profit beats estimates; should you buy now-
- Swastik Productions appoints Manish Agarvwal as head of digital, marcom and special projects
- Tata Steel begins hydrogen gas injection trial in blast furnace
- Investment-tech platform, Grip secures OBPP licence under new regulatory framework
- Indian shares set to open flat ahead of RBI rate decision
- Current rupee fall way lower than in earlier crises
- Crude oil prices fall on US debt uncertainty